N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylpent-4-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylpent-4-enamide
• 英文别名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-thiophen-2-ylpent-4-enamide
• 化学式: C₁₆H₂₂N₂O₂S
• 分子量: 306.429
• InChiKey: MFPPFFMHFODFQO-KNVGNIICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  80.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NEW QUINUCLIDINE AMIDE DERIVATIVES<br/>[FR] DERIVES DE QUINUCLIDINE AMIDE
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2004005285A1

  公开（公告）日：2004-01-15

  New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  新的喹啉啉酰胺衍生物具有通式（I）的化学结构，以及其药学上可接受的盐，包括通式（II）的季铵盐；以及它们的制备方法，包括它们的药物组合物和作为M3胆碱能受体拮抗剂在治疗中的用途。
• Quinuclidine amide derivatives
  申请人：Prat Quinones Maria

  公开号：US20060167042A1

  公开（公告）日：2006-07-27

  New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  本研究公开了具有通式(I)化学结构的新型喹吖啶酰胺衍生物及其药学上可接受的盐类，包括式(II)的季盐；以及它们的制备工艺、包含它们的药物组合物10和它们作为M3毒蕈碱受体拮抗剂在治疗中的用途。
• QUINUCLIDINE AMIDE DERIVATIVES
  申请人：Almirall, S.A.

  公开号：EP1519933B1

  公开（公告）日：2010-05-12
• JP2005533826A
  申请人：——

  公开号：JP2005533826A

  公开（公告）日：2005-11-10
• Quinuclidine Amide Derivatives
  申请人：QUINONES PRAT Maria

  公开号：US20080234316A1

  公开（公告）日：2008-09-25

  New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.